Navigation Links
Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Date:5/13/2009

SAN FRANCISCO, May 13 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference on Wednesday, May 20 in New York.

Dr. Hung will provide an overview of Medivation and its clinical development programs at 10:30 a.m. Eastern Time, which will be webcast. In addition, Dr. Hung will participate in an expert panel discussion titled, "New Developments in Solid Tumors, Focusing on GU and GI Cancers," on the same day at 8:10 a.m. Eastern Time.

A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
2. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
3. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
4. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
5. Medivation Announces Participation in Upcoming Conferences
6. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
7. Medivation Announces Participation in Upcoming Conferences
8. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
9. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
10. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
11. Genomic Health to Present at JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Calif. (PRWEB) , ... August 18, 2017 , ... Western ... in health and education to launch the University’s new Center for Innovation on Wednesday, ... WesternU Health Education Center Lecture Hall 1, followed by a technology exhibition from 1 ...
(Date:8/19/2017)... ... August 19, 2017 , ... Curl Keeper® is excited to ... Curl Leaders, Editors’ Choice 2017 Award for the second year in a row. The ... and curlies alike was voted Best Moisturizer for Type 2 Wavies and Best Refresher ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... joined its Orlando location as an interventional pain management physician. He brings a ... the treatment of migraine headaches, and significant experience in spinal cord stimulation for ...
(Date:8/18/2017)... , ... ... ... For Immediate Release                Contact: ... Shows Young Women Seek Sex and Relationship Advice from their ...
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/7/2017)... Md. , Aug. 7, 2017 ... healthcare member acquisition, retention, and engagement, announced the ... of Strategy and Product Development, effective as of ... consulting and technology implementation strategy for our clients. ... of experience in consulting and business analytics within ...
Breaking Medicine Technology: